Page last updated: 2024-08-25

rosiglitazone and mk-3118

rosiglitazone has been researched along with mk-3118 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Angulo, D; Atiee, G; Corr, C; Hyman, M; Murphy, G; Willett, M; Wring, S	1

Trials

1 trial(s) available for rosiglitazone and mk-3118

Article	Year
Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions. Journal of clinical pharmacology, 2018, Volume: 58, Issue:10 Topics: Adult; Antifungal Agents; Area Under Curve; Cytochrome P-450 CYP2C8; Drug Administration Schedule; Drug Interactions; Female; Glucosyltransferases; Glycosides; Half-Life; Humans; Male; Rosiglitazone; Triterpenes	2018

Article

Year

Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions.

Journal of clinical pharmacology, 2018, Volume: 58, Issue:10

Topics: Adult; Antifungal Agents; Area Under Curve; Cytochrome P-450 CYP2C8; Drug Administration Schedule; Drug Interactions; Female; Glucosyltransferases; Glycosides; Half-Life; Humans; Male; Rosiglitazone; Triterpenes

2018